Abeona Therapeutics IncABEO
ASignal's systematic analysis rates ABEO as Neutral.
Reflects the latest available analysis · analyzed Aug 20, 2026
The case on ABEO
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (2745% YoY)
- High cash position ($146.83M) with low debt ($19.87M)
- Low debt-to-equity ratio (0.16x)
- Current ratio of 6.63x indicating strong liquidity
- Negative RSI at 44.44, trending toward oversold
- MACD below signal line with negative histogram
- Negative price momentum (-0.11)
- Negative gross, operating, and net margins
- Negative return on equity and return on assets
- No Reddit mentions indicating low retail interest
See the full verdict on ABEO
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes ABEO
Most investors never get a second opinion, let alone several. ASignal runs ABEO past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.